載入...
Do single‐arm trials have a role in drug development plans incorporating randomised trials?
Often, single‐arm trials are used in phase II to gather the first evidence of an oncological drug's efficacy, with drug activity determined through tumour response using the RECIST criterion. Provided the null hypothesis of ‘insufficient drug activity’ is rejected, the next step could be a rand...
Na minha lista:
| 發表在: | Pharm Stat |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4855632/ https://ncbi.nlm.nih.gov/pubmed/26609689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pst.1726 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|